PTC Therapeutics, Inc.

NasdaqGS:PTCT Stock Report

Market Cap: US$3.9b

PTC Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:PTCT Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
22 Apr 25SellUS$136,656Matthew KleinIndividual2,804US$48.74
02 Apr 25SellUS$42,114Lee GoldenIndividual897US$46.95
13 Mar 25SellUS$270,000Stephanie OkeyIndividual5,000US$54.00
04 Mar 25SellUS$63,370Allan JacobsonIndividual1,230US$51.52
20 Feb 25SellUS$147,628Neil AlmsteadIndividual2,946US$50.12
20 Feb 25SellUS$147,577Eric PauwelsIndividual2,945US$50.12
20 Feb 25SellUS$147,678Mark BouldingIndividual2,947US$50.12
20 Feb 25SellUS$88,046Lee GoldenIndividual1,757US$50.12
20 Feb 25SellUS$390,457Matthew KleinIndividual7,792US$50.12
20 Feb 25SellUS$88,043Christine UtterIndividual1,757US$50.12
20 Feb 25SellUS$117,007Pierre GravierIndividual2,335US$50.12
08 Jan 25SellUS$90,036Lee GoldenIndividual2,008US$45.34
08 Jan 25SellUS$132,493Christine UtterIndividual2,953US$45.34
08 Jan 25SellUS$167,551Eric PauwelsIndividual3,735US$45.34
08 Jan 25SellUS$204,007Matthew KleinIndividual4,544US$45.34
08 Jan 25SellUS$133,674Neil AlmsteadIndividual2,979US$45.34
08 Jan 25SellUS$158,871Mark BouldingIndividual3,541US$45.34
31 Dec 24SellUS$373,880Matthew KleinIndividual8,279US$45.16
16 Jul 24SellUS$77,200Pierre GravierIndividual2,269US$34.02

Insider Trading Volume

Insider Buying: PTCT insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of PTCT?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,931,7512.38%
Hedge Funds12,917,97015.9%
Institutions66,409,74681.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 80.64% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.9%
The Vanguard Group, Inc.
8,607,372US$420.8m-6.23%0.01%
9.8%
BlackRock, Inc.
7,768,199US$379.8m-1.65%0.01%
9.44%
RTW Investments, LP
7,483,127US$365.9m1.22%5.43%
6.86%
Armistice Capital LLC
5,434,843US$265.7m-14.8%6.7%
6.84%
Wellington Management Group LLP
5,419,172US$264.9m13.2%0.04%
3.68%
Janus Henderson Group plc
2,916,729US$142.6m25.4%0.06%
3.3%
Cowen Inc,Private Banking and Investment Banking Investments
2,613,196US$127.8m-20.5%7.12%
3.1%
State Street Global Advisors, Inc.
2,454,896US$120.0m-9.35%no data
2.54%
FMR LLC
2,013,471US$98.4m146%0.01%
2.36%
Geode Capital Management, LLC
1,873,886US$91.6m4.28%0.01%
1.91%
Driehaus Capital Management LLC
1,512,645US$74.0m45.3%0.44%
1.91%
Michael Schmertzler
1,509,860US$73.8m0.35%no data
1.89%
Camber Capital Management LP
1,500,000US$73.3m-53.1%5.01%
1.83%
UBS Asset Management AG
1,448,402US$70.8m17.6%0.01%
1.82%
D. E. Shaw & Co., L.P.
1,445,279US$70.7m-6.29%0.08%
1.76%
Point72 Asset Management, L.P.
1,398,268US$68.4m-13.7%0.14%
1.6%
Franklin Resources, Inc.
1,268,072US$62.0m1.46%0.02%
1.47%
Citadel Advisors LLC
1,167,621US$57.1m155%0.06%
1.32%
Pictet Asset Management Limited
1,042,458US$51.0m41.6%0.03%
1.26%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
1,001,855US$49.0m-6.59%0.01%
1.26%
Tang Capital Management, LLC
1,000,000US$48.9m42.9%2.45%
1.11%
Morgan Stanley, Investment Banking and Brokerage Investments
877,387US$42.9m-12.6%no data
0.94%
Northern Trust Global Investments
744,011US$36.4m2.2%no data
0.93%
Marshall Wace LLP
741,002US$36.2m0%0.05%
0.85%
Renaissance Technologies LLC
670,200US$32.8m2.62%0.05%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/30 18:54
End of Day Share Price 2025/05/30 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PTC Therapeutics, Inc. is covered by 29 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Geoffrey MeachamBarclays
Huidong WangBarclays